![]() |
市場調查報告書
商品編碼
2099599
血液採集設備市場-2026-2032年全球市場預測Blood Collection Devices Market - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,血液採集設備市場規模將達到 124.3 億美元,複合年成長率為 6.14%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 81.8億美元 |
| 預計年份:2026年 | 86.6億美元 |
| 預測年份:2032年 | 124.3億美元 |
| 複合年成長率 (%) | 6.14% |
血液採集設備是診斷、輸血醫學、臨床研究、血庫和日常病患監測的基礎。此類別包括針頭和安全針頭、真空採血管、注射器、採血針、血袋、採血套裝、針架、微量血液採集系統以及相關配件,廣泛應用於醫院、診斷實驗室、門診、急診科和家庭檢測環境。全球慢性疾病和感染疾病負擔加重、預防性篩檢計畫的擴展、外科手術數量的增加、捐血需求以及循證臨床決策指南檢測的日益普及,都影響著血液採集設備的需求。
受安全性、標準化和分散化趨勢的驅動,血液採集設備市場正在經歷結構性變革。醫療專業人員優先考慮採用安全設計的針頭、伸縮式採血針、密封輸液系統和真空採血管系統,以減少職業暴露並確保檢體品質的穩定性。全球銳器安全和醫療相關感染預防的指引持續影響採購決策,尤其是在醫院和高通量診斷實驗室。
人工智慧 (AI) 對血液採集設備的價值鏈的影響日益顯著,尤其是在與自動化、數位識別和實驗室資訊系統相結合時。在臨床環境中,AI 驅動的排班、需求預測和工作流程最佳化可以縮短患者等待時間、最佳化採血人員配置並改善檢體流轉。此外,電腦視覺和基於感測器的系統也正在被探索用於支援靜脈可視化、血液採集驗證以及在高通量環境下減少錯誤。
亞太地區是血液採集設備市場最具活力的地區之一,這主要得益於醫療基礎設施的不斷完善、診斷檢測的廣泛應用、公共衛生篩檢計畫的推進以及公立和私立檢測網路的日益普及。儘管中國、印度、日本、韓國、澳洲和東協等國的診斷能力正在不斷提升,但慢性病管理、感染疾病監測、孕產婦保健計畫以及血液安全措施的持續推進,也進一步促進了靜脈和毛細血管血液採集產品的廣泛應用。該地區的採購趨勢日益受到價格因素、本地生產能力、監管協調、培訓需求以及對可靠安全設備的需求等因素的影響。
在東協,透過加大公共衛生投入、擴大私人檢測實驗室以及加強慢性病篩檢,診斷網路正在加強。由於該地區的多樣性,實施模式各不相同。高所得國家的醫療衛生系統優先考慮自動化和安全設計的採血設備,而新興國家的醫療衛生系統則更重視價格可負擔性、可靠的供應、廣泛的分銷網路以及在都市區醫療機構中開展標準化採血技術培訓。
在美國,市場特徵是診斷檢測量大、職業安全要求嚴格、醫院和實驗室網路覆蓋廣泛,以及持續採用安全設計的針頭、真空採血管、採血袋和專用採血系統。加拿大同樣重視品質和安全,其採購受到公共醫療體系、感染控制標準、檢查室整合以及國家層級強調公平取得診斷檢測服務的影響。墨西哥市場正在擴張,這得益於私人診斷檢測的成長、公共衛生檢測的增加、醫院投資的成長以及與北美醫療供應鏈的接近性。同時,巴西憑藉其醫院網路、對血庫的需求、公共衛生項目以及對感染疾病和慢性病檢測的需求,保持其在拉丁美洲主要市場的地位。
產業領導者應優先考慮以安全為核心的產品系列設計,並專注於針刺傷預防、感染控制以及符合職業健康要求。產品開發應著重於減少溶血、提高灌裝精度、增強試管添加劑的一致性、提升病患舒適度、支援小容量和毛細血管採血,並確保與自動化檢查室系統和數位化追溯系統相容。
本執行摘要採用系統化的二手資料研究途徑編寫,重點關注檢驗的醫學、監管、臨床和行業資訊來源。此調查方法優先考慮來自公共衛生機構、醫療設備監管機構、職業安全指南、臨床實驗室標準、同行評審文獻、血液安全參考資料、醫療保健基礎設施指標以及權威的診斷和臨床實驗室醫學出版物的證據。
血液採集設備正從單純的臨床耗材演變為安全、標準化和數位化互聯診斷的關鍵基礎。安全法規、自動化檢查室工作流程、以患者為中心的血液採集、分散式醫療、血液安全優先事項以及對可追溯性和檢體完整性日益成長的期望,都在推動著這一領域的變革。人工智慧 (AI) 透過改善工作流程規劃、品質監控、供應鏈可靠性和數據驅動的檢查室運營,進一步加速了這項變革。
The Blood Collection Devices Market is projected to grow by USD 12.43 billion at a CAGR of 6.14% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 8.18 billion |
| Estimated Year [2026] | USD 8.66 billion |
| Forecast Year [2032] | USD 12.43 billion |
| CAGR (%) | 6.14% |
Blood collection devices are foundational to diagnostics, transfusion medicine, clinical research, blood banking, and routine patient monitoring. The category includes needles and safety needles, evacuated blood collection tubes, syringes, lancets, blood bags, collection sets, holders, microcollection systems, and related accessories used across hospitals, diagnostic laboratories, ambulatory care centers, emergency departments, and home-based testing environments. Demand is shaped by the global burden of chronic and infectious diseases, expanding preventive screening programs, increasing surgical volumes, blood donation requirements, and the growing use of laboratory testing to guide evidence-based clinical decisions.
Industry priorities are moving beyond basic sample acquisition toward safer, faster, and more reliable preanalytical workflows. Regulatory emphasis on needlestick injury prevention, specimen integrity, traceability, hemolysis reduction, and infection control is accelerating adoption of safety-engineered and closed blood collection systems. At the same time, laboratory automation, point-of-care diagnostics, decentralized clinical trials, and patient-centric care models are reshaping device design and procurement criteria. For stakeholders across the blood collection devices ecosystem, competitiveness increasingly depends on product reliability, usability, compliance readiness, supply continuity, and integration with digital healthcare workflows.
The blood collection devices landscape is undergoing a structural shift driven by safety, standardization, and decentralization. Healthcare providers are prioritizing safety-engineered needles, retractable lancets, closed transfer systems, and evacuated tube systems that reduce occupational exposure and support consistent sample quality. Global guidance on sharps safety and healthcare-associated infection prevention continues to influence purchasing policies, especially in hospitals and high-volume diagnostic laboratories.
A second major shift is the rise of patient-centric and minimally invasive collection. Capillary blood collection, microsampling, and dried blood spot approaches are gaining relevance in pediatrics, geriatrics, chronic disease monitoring, remote care, and clinical studies where convenience and low-volume sampling matter. This trend is supported by broader adoption of at-home testing, telehealth-linked diagnostics, and decentralized trial models.
The third shift is operational: laboratories and healthcare systems are demanding devices that minimize preanalytical errors. Tube additive accuracy, barcode compatibility, sample stability, fill-volume precision, and compatibility with automated analyzers are now central purchasing considerations. Sustainability is also influencing product development, with greater attention to packaging reduction, responsible plastics use, sterilization efficiency, and waste handling in regulated healthcare settings.
Artificial intelligence is increasingly influencing the blood collection devices value chain, although its impact is most visible when combined with automation, digital identification, and laboratory information systems. In clinical settings, AI-enabled scheduling, demand prediction, and workflow orchestration can help reduce patient wait times, optimize phlebotomy staffing, and improve sample routing. Computer vision and sensor-based systems are also being explored to support vein visualization, collection verification, and error reduction in high-throughput environments.
Across laboratories, AI supports detection of preanalytical quality issues such as insufficient volume, clotting, labeling discrepancies, delayed transport, and hemolysis risk when paired with automated inspection and data capture systems. This strengthens the value proposition for blood collection devices designed with digital traceability, barcode readability, standardized tube geometry, and compatibility with automated processing lines.
In manufacturing and supply chains, AI contributes to quality analytics, predictive maintenance, demand planning, and lot-level traceability. These capabilities are especially important for products requiring sterility assurance, consistent material performance, and regulatory documentation. The cumulative impact of AI is therefore not a replacement of core collection devices, but an elevation of performance expectations: devices must increasingly fit into intelligent diagnostic ecosystems where safety, data integrity, traceability, and workflow efficiency are interconnected.
Asia-Pacific is one of the most dynamic regions for blood collection devices due to expanding healthcare infrastructure, rising diagnostic test utilization, public health screening programs, and increasing access to private and public laboratory networks. China, India, Japan, South Korea, Australia, and ASEAN economies are strengthening diagnostic capacity, while chronic disease management, infectious disease surveillance, maternal health programs, and blood safety initiatives continue to support broad use of venous and capillary collection products. Procurement in the region is increasingly shaped by affordability, local manufacturing capacity, regulatory harmonization efforts, training needs, and demand for reliable safety-engineered devices.
North America remains highly advanced in safety compliance, laboratory automation, and quality management. The United States and Canada emphasize needlestick injury prevention, standardized phlebotomy practices, blood banking quality, and integration with electronic health records and laboratory information systems. Adoption is supported by high diagnostic testing intensity, a mature hospital network, widespread accreditation practices, and strong demand for evacuated blood collection tubes, safety needles, microcollection products, and specialty collection systems used in advanced testing.
Latin America is progressing through modernization of clinical laboratories, expansion of private diagnostic chains, and public health initiatives focused on infectious disease testing, maternal health, blood donation services, and chronic disease monitoring. Brazil and Mexico are important demand centers, while regional procurement often balances cost control with the need for improved sample quality, safer collection practices, reliable distribution, and standardized training for phlebotomy personnel.
Europe demonstrates strong regulatory discipline, occupational safety standards, and sustainability expectations. The region's healthcare systems emphasize product conformity, traceability, patient safety, post-market surveillance, and environmental responsibility, encouraging adoption of closed systems, safety-engineered sharps, and standardized collection workflows. Western European countries tend to lead in laboratory automation and digital laboratory integration, while Central and Eastern European systems continue upgrading diagnostic infrastructure and procurement quality standards.
The Middle East is investing in hospital modernization, medical tourism, specialty care, and national diagnostic capacity. GCC countries are particularly focused on high-quality healthcare infrastructure, digital health, and internationally aligned clinical standards, supporting demand for premium blood collection devices and automated laboratory-compatible products. Africa presents a different but significant opportunity profile, with needs centered on blood safety, infectious disease diagnostics, maternal and child health, outbreak preparedness, and decentralized testing. Progress in the region depends heavily on resilient distribution, affordability, healthcare worker training, donor-supported healthcare programs, cold-chain and logistics readiness, and devices suitable for varied infrastructure conditions.
ASEAN countries are strengthening diagnostic networks through public health investment, private laboratory expansion, and growing chronic disease screening. The group's diversity creates varied adoption patterns: higher-income healthcare systems prioritize automation-compatible and safety-engineered blood collection devices, while emerging systems emphasize affordability, supply reliability, distribution reach, and training for standardized phlebotomy practices across urban and decentralized care settings.
The GCC is characterized by rapid healthcare modernization, hospital accreditation initiatives, digital health investment, and strong demand for premium clinical consumables. Blood collection device procurement in the GCC is influenced by international quality standards, infection control policies, advanced laboratory infrastructure, and the need to support specialty clinics, hospital laboratories, emergency care, and blood transfusion services.
The European Union places strong emphasis on regulatory conformity, medical device safety, environmental stewardship, and cross-border quality expectations. EU healthcare systems are attentive to medical device documentation, post-market surveillance, occupational health protections, and sustainability in healthcare procurement, which supports sustained preference for validated safety needles, evacuated tube systems, closed transfer devices, and standardized blood collection workflows.
BRICS economies represent a broad and influential demand base for blood collection devices, driven by large populations, healthcare access expansion, infectious and chronic disease testing needs, blood banking requirements, and increasing domestic manufacturing capabilities. China and India are especially important for scale and local production, while Brazil, Russia, and South Africa add demand through public health systems, hospital networks, laboratory modernization, and national priorities for supply resilience.
G7 countries generally show mature adoption of safety-engineered, automation-ready, and specialty blood collection devices. These markets focus on quality assurance, regulatory compliance, patient comfort, workforce protection, diagnostic accuracy, and digital integration across healthcare delivery. NATO countries overlap substantially with high-standard healthcare systems, where procurement resilience, supply chain security, emergency preparedness, and standardized medical logistics have gained strategic importance, particularly for essential clinical consumables including blood collection products.
The United States is shaped by high diagnostic testing volumes, strong occupational safety requirements, broad hospital and laboratory networks, and continued adoption of safety-engineered needles, evacuated tubes, blood bags, and specialty collection systems. Canada follows similar quality and safety priorities, with procurement influenced by public healthcare structures, infection prevention standards, laboratory consolidation, and national emphasis on equitable access to diagnostics. Mexico is advancing through private diagnostics expansion, public health testing, growing hospital investment, and proximity to North American medical supply chains, while Brazil remains a key Latin American market supported by hospital networks, blood banking needs, public health programs, and infectious disease and chronic disease testing demand.
In Europe, the United Kingdom emphasizes laboratory efficiency, patient safety, standardized diagnostics, and workforce protection across public and private care settings. Germany is distinguished by advanced clinical laboratories, strong manufacturing standards, robust quality systems, and demand for precision and automation-compatible blood collection products. France maintains strong emphasis on healthcare quality, infection control, regulated procurement, and traceable laboratory workflows. Russia's demand is tied to hospital infrastructure, public healthcare needs, blood service requirements, and domestic supply considerations. Italy and Spain support steady use of blood collection devices through mature healthcare systems, chronic disease management, blood donation services, hospital networks, and diagnostic laboratory capacity.
China is a major force in blood collection device demand and production, supported by hospital expansion, population-scale diagnostics, public health programs, domestic manufacturing, and growing regulatory sophistication. India's demand is driven by a large patient population, rising diagnostic access, chronic disease screening, infectious disease testing, and expansion of organized laboratory chains, with affordability, training, and supply reach remaining critical. Japan emphasizes high-quality, precision-engineered devices, patient comfort, and reliable preanalytical performance in an advanced healthcare environment. Australia prioritizes safety, quality, and standardized collection protocols across public and private care settings, while South Korea combines strong hospital infrastructure, advanced diagnostics, digital health readiness, and high laboratory standards, supporting demand for high-performance and automation-compatible blood collection products.
Industry leaders should prioritize safety-engineered product portfolios that address needlestick prevention, infection control, and compliance with occupational health expectations. Product development should focus on reducing hemolysis, improving fill accuracy, strengthening tube additive consistency, enhancing patient comfort, supporting low-volume and capillary sampling, and ensuring compatibility with laboratory automation and digital traceability systems.
Manufacturers and suppliers should build resilient, regionally diversified supply chains for critical materials, sterilization capacity, packaging, and distribution. Procurement teams increasingly value continuity of supply, lot-level documentation, validated quality systems, and rapid responsiveness during public health emergencies. Companies should also invest in clinician training, phlebotomy education, and clear instructions for use, as user technique remains a major determinant of sample quality and preanalytical reliability.
To compete in evolving diagnostic ecosystems, stakeholders should align blood collection devices with laboratory information systems, barcoding standards, automated analyzers, and emerging AI-enabled quality workflows. Sustainability should be embedded into product design and packaging strategies without compromising sterility, safety, or regulatory compliance. In emerging markets, leaders should balance affordability with durable quality, training support, and distribution models suited to decentralized healthcare delivery.
This executive summary is developed using a structured secondary research approach focused on verified healthcare, regulatory, clinical, and industry sources. The methodology prioritizes evidence from public health agencies, medical device regulatory authorities, occupational safety guidance, clinical laboratory standards, peer-reviewed literature, blood safety references, healthcare infrastructure indicators, and recognized diagnostics and laboratory medicine publications.
The analysis examines demand drivers, technology shifts, safety requirements, regional healthcare dynamics, diagnostic testing trends, and procurement priorities without using market sizing, market share, or forecasting. Regional, group, and country insights are synthesized through comparative evaluation of healthcare system maturity, laboratory infrastructure, regulatory direction, disease burden, public health testing needs, blood banking requirements, reimbursement context, workforce readiness, and supply chain considerations. Findings are validated through cross-source consistency checks and are presented as qualitative, data-backed strategic insights for decision-makers in the blood collection devices ecosystem.
Blood collection devices are evolving from routine clinical consumables into critical enablers of safe, standardized, and digitally connected diagnostics. The sector is being reshaped by safety regulations, automation-ready laboratory workflows, patient-centric sampling, decentralized care, blood safety priorities, and rising expectations for traceability and sample integrity. Artificial intelligence further amplifies these changes by improving workflow planning, quality monitoring, supply chain reliability, and data-driven laboratory operations.
Regional opportunities vary significantly: advanced healthcare systems emphasize automation, compliance, and premium safety features, while emerging regions prioritize access, affordability, resilient supply, and workforce training. Across all settings, the strongest strategic position will belong to stakeholders that combine device reliability, regulatory readiness, user-centered design, digital compatibility, and sustainable operations. As diagnostics remain central to modern healthcare, blood collection devices will continue to play an essential role in improving clinical decision-making, patient safety, transfusion readiness, and public health resilience.